Highly active antiretroviral therapy (HAART) is associated with metabolic adverse events such as @entity2690 resistance and @entity6562 , that is, @entity194 of subcutaneous fat and accumulation of intra-abdominal fat. Currently, there is no pharmacological treatment for @entity3388 . @entity12721 , a novel class of @entity2690 -sensitizing anti- @entity6 agents, increase subcutaneous fat in @entity1 with @entity164 2 @entity6 . There are no controlled studies of @entity12721 in @entity1 with @entity34 ( @entity34 ). In this randomized, double-blind, placebo-controlled study, 30 @entity1 with @entity34 received either @entity6170 (8 mg daily) or placebo for 24 weeks. Baseline characteristics were compared to a group of 30 age-, sex- and weight-matched @entity645 -negative controls. At baseline, @entity1 with @entity34 had 1.8-fold (P<0.001) more intra-abdominal and 2.4-fold (P<0.05) more liver fat than @entity645 -negative controls, who had 1.8-fold (P<0.001) more subcutaneous fat than the @entity1 . After 24 weeks of treatment, @entity6170 had no effect on body weight, subcutaneous or intra-abdominal fat (magnetic resonance imaging), total body fat (bioimpedance analysis), anthropometric measurements or serum leptin concentrations (a circulating marker of adipose tissue mass). However, @entity6170 decreased % liver fat (spectroscopy) and serum @entity2690 concentrations, and normalized liver function tests. During the first 12 weeks of @entity6170 treatment, serum @entity1674 increased from 3.5 +/- 0.5 to 6.5 +/- 2.0 mmol/l (from 310 +/- 44 to 575 +/- 177 mg/dl) (P<0.05) and serum @entity165 from 6.0 +/- 0.4 to 7.8 +/- 0.7 mmol/l (from 232 +/- 15 to 301 +/- 27 mg/dl) (P<0.01). Contrary to data in other @entity1 groups, @entity6170 did not increase subcutaneous fat in @entity1 with @entity34 after 24 weeks of treatment. @entity6170 seemed to ameliorate @entity2690 resistance judged by the decreased serum @entity2690 concentrations and % liver fat. @entity6170 unexpectedly caused significant increases in serum @entity412 and @entity165 concentrations, which must be carefully monitored if @entity12721 are used in these @entity1 .

XXXX in the treatment of @entity34 --a randomized double-blind placebo-controlled study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity6562 :: ('MESH:D008060', 'Disease') :: ['lipodystrophy'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity2690 :: ('3630', 'Gene') :: ['insulin'] @entity645 :: ('57667', 'Species') :: ['HIV'] @entity12721 :: ('MESH:D045162', 'Chemical') :: ['Glitazones', 'glitazones'] @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride'] @entity194 :: ('MESH:D001284', 'Disease') :: ['atrophy'] @entity164 :: ('MESH:D017827', 'Disease') :: ['type'] @entity3388 :: ('MESH:C535905', 'Disease') :: ['lipoatrophy'] @entity6170 :: ('MESH:C089730', 'Chemical') :: ['Rosiglitazone', 'rosiglitazone'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol'] @entity34 :: ('MESH:D016609', 'Disease') :: ['HAART-associated lipodystrophy', 'HAL']
@entity6170 :: (MESH:C089730,Chemical) :: ['Rosiglitazone']
